Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.43 |
| ▸ | NPY1R | P25929 | 7/20 | 0.43 |
| ▸ | NPY2R | P49146 | 5/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | NMT2 | O60551 | 1/20 | 0.36 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
| ▸ | GNPAT | O15228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30997467 | 1.00 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL30997455 | 1.00 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL30997438 | 1.00 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL30997484 | 1.00 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL30997446 | 1.00 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29669218 | 0.99 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL30571130 | 0.99 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29576308 | 0.96 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RTGFBR1 | |
| SCHEMBL31522358 | 0.96 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL19554702 | 0.96 | NPY4R (0.43) | NPY4RNPY1RNPY2RNPY5RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | claimed |
| WO-2025092703-A1 | PHOTOSENSITIZER CONJUGATE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 同宜医药（苏州）有限公司 | 2025-05-08 | — | — | WO | claimed |
| CN-119909192-A | Photosensitizer conjugate compound, pharmaceutical composition and application thereof | 同宜医药（苏州）有限公司 | 2025-05-02 | — | — | CN | claimed |
| EP-4512426-A1 | COMPOUND AND USE THEREOF | Coherent Biopharma (Suzhou), Limited (CN) | 2025-02-26 | — | — | EP | claimed |
| CN-119031938-A | Compounds and uses | 同宜医药（苏州）有限公司 | 2024-11-26 | — | — | CN | claimed |
| WO-2023202654-A1 | COMPOUND AND USE THEREOF | 同宜医药（苏州）有限公司 | 2023-10-26 | — | — | WO | claimed |
| CN-111617250-B | Multi-ligand drug couplet and application thereof | 同宜医药（苏州）有限公司 | 2022-07-01 | — | — | CN | claimed |
| US-20220175761-A1 | BI-LIGAND DRUG CONJUGATE AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2022-06-09 | — | — | US | claimed |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| WO-2025092703-A1 | PHOTOSENSITIZER CONJUGATE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 同宜医药（苏州）有限公司 | 2025-05-08 | — | — | WO | disclosed |
| CN-119909192-A | Photosensitizer conjugate compound, pharmaceutical composition and application thereof | 同宜医药（苏州）有限公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4512426-A1 | COMPOUND AND USE THEREOF | Coherent Biopharma (Suzhou), Limited (CN) | 2025-02-26 | — | — | EP | disclosed |
| CN-119031938-A | Compounds and uses | 同宜医药（苏州）有限公司 | 2024-11-26 | — | — | CN | disclosed |
| US-20240358843-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2024-10-31 | — | — | US | disclosed |
| EP-4360654-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | Coherent Biopharma (Suzhou), Limited (CN) | 2024-05-01 | — | — | EP | disclosed |
| WO-2023202654-A1 | COMPOUND AND USE THEREOF | 同宜医药（苏州）有限公司 | 2023-10-26 | — | — | WO | disclosed |
| WO-2022268202-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | 同宜医药（苏州）有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-20220175761-A1 | BI-LIGAND DRUG CONJUGATE AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175761-A1 | BI-LIGAND DRUG CONJUGATE AND USE THEREOF | SLC10A1, CD47, SELPLG | NPY4R 1215/4885NPY1R 1725/4885NPY2R 1327/4885 |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | FOLH1, TRPV6, FOLR1 | NPY4R 627/4885NPY1R 569/4885NPY2R 275/4885 |
| US-20240358843-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SELPLG, SELL, SIGLEC7 | NPY4R 2426/4885NPY1R 2946/4885NPY2R 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.